What an IDS Really Is
In U.S. patent prosecution, applicants and others substantively involved in preparing or prosecuting the application owe the USPTO a duty of candor and good faith. That duty includes disclosing known information that is material to patentability. The usual vehicle is an Information Disclosure Statement, or IDS.
This is different from the default intuition many Chinese applicants bring from CNIPA practice. In China, applicants often expect the examiner to perform the prior-art search and then respond to what the office finds. In the United States, examination still involves examiner searching, but the applicant cannot sit silently on material references it already knows about, including references cited in related Chinese, European, Japanese, Korean, or PCT family members.
That is why IDS practice can feel like paying someone to strengthen the rejection against you. Sometimes, if handled carelessly, that is exactly what it becomes: a large, expensive packet of references that makes the examiner's work easier without giving the applicant any corresponding strategic benefit.
The Real Risk Is Not the First Office Action
If an applicant chooses not to submit known material art, the short-term result may look good. The examiner may not find the reference. The case may issue faster. The applicant may feel it saved IDS attorney fees.
That apparent savings can collapse in litigation. A U.S. patent is not merely a certificate; it is a litigation asset. When the patent is asserted against a competitor, opposing counsel will investigate the entire patent family. They will compare U.S. prosecution against CNIPA search reports, EPO communications, PCT international search reports, invalidity searches, and internal development records. If a highly relevant reference appeared in a Chinese counterpart but was never submitted to the USPTO, the issue is no longer a routine prosecution detail.
The accusation may become inequitable conduct: that someone involved in prosecution knew about material information and intentionally withheld it. If the defense succeeds, the patent can become unenforceable. A technically valuable patent then becomes a weapon that cannot be used at the moment it matters most.
The dangerous scenario is not submitting too much in one batch. It is knowingly withholding a material family reference because it looks harmful. That decision may save a small prosecution cost and create a much larger enforcement risk.
But Over-Disclosure Has a Cost Too
Compliance does not mean dumping every document ever touched by the company into the USPTO file. An indiscriminate IDS can create three problems.
First, it increases attorney time. U.S. counsel must format, check, categorize, and submit the documents correctly. Second, it may trigger official costs, including timing fees and, for large cumulative submissions, IDS size fees. Third, it may bury the truly important references among marginal references, making prosecution less focused and more expensive.
The business goal is therefore not "submit as much as possible." The goal is to submit what must be submitted, at the right time, in a way that creates a clean record and minimizes repeated U.S. attorney work.
A Cost-Control Strategy for Chinese Applicants
IDS work should be designed as a family-management workflow, not as a series of panicked emails to U.S. counsel.
That internal table is not clerical busywork. It is the cheapest place to do the comparison. If the company asks U.S. counsel to determine which Chinese search report documents were already submitted, which are duplicates, which need English explanations, and which fall into a late-IDS window, the invoice will reflect that work. When the applicant's team performs the first-level organization, U.S. counsel can focus on legal review and filing.
A Practical IDS Workflow
For each patent family with a U.S. case pending, create a simple living record with these fields:
- Reference number, publication number, patent number, or NPL citation.
- Source of discovery: CNIPA search report, EPO search opinion, PCT ISR, competitor search, inventor disclosure, or other source.
- Date first known to the applicant or prosecution team.
- Date cited by a foreign patent office, if applicable.
- Whether the reference is cumulative of art already submitted in the U.S.
- Whether an English abstract, machine translation, or concise explanation of relevance is available.
- U.S. IDS submission date and confirmation of examiner consideration.
This record also helps manage timing. Under USPTO rules, an IDS filed in the early window is treated differently from one filed after that window. If the reference came from a foreign office communication in a counterpart application, the three-month timing of that communication may matter for whether a 37 CFR 1.97(e) statement can be made. That is why a six-month batching cycle may be too relaxed for some portfolios; a quarterly review is often safer.
The Business Message
IDS compliance is a cost of entering the U.S. patent system. It is not a sign that U.S. counsel is working against the applicant, and it is not a task that should be ignored until allowance. The right question is not whether to disclose known material information. The right question is how to disclose it efficiently, early, and with enough internal organization that the company does not pay U.S. hourly rates for basic family bookkeeping.
For Chinese companies building U.S. patent portfolios, the mature approach is simple: do not hide damaging references, do not flood the file blindly, and do not outsource the entire tracking burden. Treat IDS practice as a portfolio-control process. The money spent on a disciplined IDS record is far cheaper than the cost of discovering, during U.S. litigation, that the patent cannot be enforced.